Investing.com - Maravai Lifesciences (NASDAQ: MRVI) reported fourth quarter EPS of $0.01, $0.02 better than the analyst estimate of $-0.01. Revenue for the quarter came in at $74.1M versus the consensus estimate of $64.57M.
Guidance
Maravai Lifesciences sees FY 2024 revenue of $265.00M-$285.00M versus the analyst consensus of $261.00M.
Maravai Lifesciences's stock price closed at $5.11. It is down -4.49% in the last 3 months and down -65.84% in the last 12 months.
Maravai Lifesciences saw 0 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Maravai Lifesciences's stock price’s past reactions to earnings here.
According to InvestingPro, Maravai Lifesciences's Financial Health score is "good performance".
Check out Maravai Lifesciences's recent earnings performance, and Maravai Lifesciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar